Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease

NCT: NCT07834372 · NOT_YET_RECRUITING

NCT IDNCT07834372
StatusNOT_YET_RECRUITING
Start Date2026-10
Completion2029-04
SponsorHeartFlow, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

REWRITE-CAD is a prospective, randomized, multi-center trial assessing the management of asymptomatic participants with a history of PCI or MI who will undergo a blinded CCTA and be randomly assigned to either the test arm in which participants receive the unblinded results of Heartflow AI-CPA or the usual care arm in which participants are blinded to the AI-CPA results.

Frequently Asked Questions

What is REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease?

REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease is a clinical trial registered under NCT07834372. Current status: NOT_YET_RECRUITING.

What is the status of NCT07834372?

The current status of NCT07834372 (REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease) is: NOT_YET_RECRUITING.

When did REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease start?

REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease started on 2026-10.

Related Devices

K152733FFRctHeartFlow, Inc. K161772FFRctHeartFlow, Inc. K182035FFRctHeartFlow, Inc. K190925HeartFlow FFRct AnalysisHeartFlow, Inc. K203329HeartFlow AnalysisHeartFlow, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑